Physician profile
Amanda Ellenburg
NPI 1013442664
$6,458.67
in general payments reported to CMS, 2019-2025
33 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,563 · 2022: $2,055 · 2023: $1,854 · 2024: $496 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,778 · Education: $62.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.08 |
| Education | $62.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,537.17 | 2021-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $798.87 | 2021-2024 | Rybelsus, Ozempic, Tresiba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $721.12 | 2021-2023 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $507.25 | 2022-2025 | |
| Lilly USA, LLC | $492.84 | 2021-2023 | Jardiance, Mounjaro, Trulicity |
| Glaxosmithkline, LLC. | $388.18 | 2021-2025 | Shingrix, Penmenvy, Trelegy Ellipta |
| Amarin Pharma, INC. | $246.53 | 2021 | |
| Gilead Sciences, INC. | $171.88 | 2021-2022 | |
| Amgen INC. | $158.91 | 2023 | Repatha, Otezla |
| Ironwood Pharmaceuticals, INC | $137.20 | 2021-2023 | Linzess |
| Merck Sharp & Dohme LLC | $124.98 | 2025 | Capvaxive |
| Sobi, INC | $120.75 | 2023 | |
| Sunovion Pharmaceuticals INC. | $119.76 | 2022 | |
| Medical Device Business Services, INC. | $99.74 | 2023 | Linx Reflux Management System |
| Abbvie INC. | $93.41 | 2021-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $90.39 | 2022 | |
| Sumitomo Pharma America, INC. | $82.34 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $77.95 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $74.68 | 2021-2023 | |
| Pfizer INC. | $68.82 | 2021-2023 | |
| Eisai INC. | $67.28 | 2021-2022 | |
| Abbott Laboratories | $46.62 | 2021-2023 | Freestyle Libre 3 |
| Boston Scientific Corporation | $39.21 | 2022-2023 | |
| Esperion Therapeutics, INC. | $33.34 | 2021 | |
| Arbor Pharmaceuticals, INC. | $24.99 | 2021 | |
| Horizon Therapeutics Plc | $20.51 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.66 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $19.27 | 2022 | |
| Mannkind Corporation | $17.05 | 2022 | |
| Exact Sciences Corporation | $14.97 | 2023 | Cologuard Collection Kit |
| Philips North America LLC | $14.57 | 2023 | |
| Hikma Pharmaceuticals USA | $14.56 | 2021 | |
| Dexcom, INC. | $13.87 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Ellenburg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.